<DOC>
	<DOCNO>NCT01061593</DOCNO>
	<brief_summary>Dzherelo ( Immunoxel ) oral immunomodulating botanical agent available over-the-counter Ukraine . After many year laboratory clinical test formulation approve 1997 Ministry Health Ukraine dietary herbal supplement , enhance immunity viral infectious disease . The goal study conduct confirmatory clinical trial Ukraine Mongolia TB indication .</brief_summary>
	<brief_title>Adjunct Immunotherapy With Immunoxel Patients With TB TB/HIV</brief_title>
	<detailed_description>Phase III , placebo-controlled trial , aim seek therapeutic benefit Immunoxel combination standard care anti-TB therapy ( ATT ) end 1-month period ( p &lt; 0.05 ) among subject sputum-positive pulmonary TB . The result compare standard ATT therapy + placebo . The trial consist one stage laboratory evaluation one month . Two cohort arm least 150 subject ( total 300 ) pulmonary TB positive sputum AFB smear randomize 1:1 ratio receive once-daily , honey lozenge Immunoxel combination standard ATT 1 month . Patients receive standard ATT + placebo preparation use group comparison .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects least 18 year willing capable providing inform consent . Both men nonpregnant woman include . One group least 30 patient HIV . Another group least 30 patient MDRTB . Another group least 30 patient XDRTB Remaining patient drugsensitive TB . They randomly assign placebo 1:1 ratio . TB infection document prior Study Entry sputum smear positive staining acidfast bacillus ( AFB ) . Agreement participate study give sample blood HIV testing require . Readily available home address patient easily find followup study . Subjects already take Immunoxel prior trial without sufficient baseline data . Those met inclusion criterion retrospectively enrol . Those retreat relapse eligible long drug regimen rest patient . Pregnant breastfeed woman exclude . Subjects take antiretroviral drug immunomodulatory therapy within 2 month prior Entry : systemic corticosteroid , immune globulin ( IV gamma globulin , IVIG ) , interferon , interleukin , pentoxifylline ( Trental ) , thalidomide , filgrastim ( GCSF ) , sargramostim ( GMCSF ) ; dinitrochlorobenzene ( DNCB ) , thymosin alpha 1 ( thymosin alpha ) , thymopentin , inosiplex ( Isoprinosine ) , polyribonucleoside ( Ampligen ) , ditiocarb sodium ( Imuthiol ) , locally available immune modulators , therapeutic preventive vaccine . Subjects require concurrent participation another experimental research treatment study , receive experimental agent within four week prior Study Entry . History angina , cardiac arrhythmia , clinically significant electrocardiogram abnormality , congestive heart failure . Evidence active acute cardiac disease , concomitant hypertension , epilepsy , serious form extrapulmonary tuberculosis . History malignancy , minimal Kaposi sarcoma localize skin cancer ( e.g . &lt; 10 cutaneous lesion , evidence visceral KS , etc . ) , prior cancer chemotherapy . Medical condition opinion local investigator , may obscure proper observation safety activity study treatment ; include acute medical condition unknown etiology recent surgery prior Entry . Medical condition active alcohol substance abuse , psychological issue opinion local investigator , would interfere adherence requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>TB</keyword>
	<keyword>MDR-TB</keyword>
	<keyword>XDR-TB</keyword>
	<keyword>TB/HIV</keyword>
</DOC>